- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Aclarion, Inc.: Aclarion Publishes 2026 Shareholder Letter from the Chairman | 119 | GlobeNewswire (Europe) | Company anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo., Feb. 05, 2026... ► Artikel lesen | |
| Di | Aclarion partners with Source Healthcare to expand Nociscan availability | 1 | Investing.com | ||
| Di | Aclarion erweitert Verfügbarkeit von Nociscan durch Partnerschaft mit Source Healthcare | 2 | Investing.com Deutsch | ||
| Di | Aclarion, Inc.: Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation | 1 | GlobeNewswire (USA) | ||
| ACLARION Aktie jetzt für 0€ handeln | |||||
| 13.01. | Aclarion raises $10.4 million to fund chronic back pain technology | 3 | Investing.com | ||
| 13.01. | Aclarion schließt Finanzierung über 10,4 Millionen US-Dollar für Technologie gegen Rückenschmerzen ab | 8 | Investing.com Deutsch | ||
| 13.01. | Aclarion, Inc.: Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028 | 389 | GlobeNewswire (Europe) | BROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers... ► Artikel lesen | |
| 09.01. | Aclarion, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.01. | Aclarion Stock Climbs 50% After Strong 2025 Results And 2026 Outlook | 9 | RTTNews | ||
| 08.01. | Aclarion-Aktie steigt sprunghaft an: Scan-Volumen von Nociscan im 4. Quartal um 114 % gewachsen | 11 | Investing.com Deutsch | ||
| 08.01. | Aclarion's AI Back Pain Tech Sees 114% Surge In Demand, Stock Soars | 9 | Benzinga.com | ||
| 08.01. | Aclarion to enroll around 25% of patients in CLARITY trial by Q2 | 3 | Seeking Alpha | ||
| 08.01. | Aclarion, Inc.: Aclarion Provides 2025 Update and 2026 Corporate Outlook | 171 | GlobeNewswire (Europe) | Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025Annual Nociscan scan volumes increased 69% year-over-year in 2025Debt-free balance sheet with $12.0 million in cash as of December... ► Artikel lesen | |
| 06.01. | Aclarion, Inc.: Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data | 85 | GlobeNewswire (Europe) | Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and operational... ► Artikel lesen | |
| 04.12.25 | Aclarion-Aktie steigt nach Vorstellung von Wirbelsäulen-Technologie in Fachjournal | 4 | Investing.com Deutsch | ||
| 04.12.25 | Aclarion's Nociscan featured in special pain issue of spine journal | 1 | Investing.com | ||
| 04.12.25 | Aclarion, Inc.: Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS) | 1 | GlobeNewswire (USA) | ||
| 12.11.25 | Aclarion: Interview With CEO Brent Ness About The Digital Health Company Addressing A Worldwide Epidemic | 4 | pulse2.com | ||
| 12.11.25 | Aclarion, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11.25 | Aclarion appoints first UK commercial director as insurance coverage expands | 1 | Investing.com |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 232,15 | -0,77 % | Märkte am Morgen: Bitcoin rauscht ab - Gold, Silber, Strategy, Amazon, UnitedHealth, SAP, Bayer | Der DAX kommt weiter nicht in die Gänge. Gestern startete der Leitindex zwar ordentlich, rutschte dann aber deutlich ab. Immerhin reduzierte er seine Verluste kurz vor Handelsende etwas. Heute deuten... ► Artikel lesen | |
| INTUITIVE SURGICAL | 413,35 | +0,02 % | INTUITIVE SURGICAL INC - 10-K, Annual Report | ||
| THERMO FISHER | 460,70 | +0,35 % | Thermo Fisher to Close Franklin, Mass. Site, Cut Up to 80 Jobs | ||
| ROKU | 73,07 | +0,63 % | This Roku Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday | ||
| ATOSSA THERAPEUTICS | 0,001 | -100,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 02.02.2026 | The following instruments on XETRA do have their first trading 02.02.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.02.2026
Aktien
1 CA00249P1053 AXA S.A. CDR
2 ARP125991090... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| CENTENE | 31,960 | -1,74 % | Centene Guides FY26 Adj. EPS Above Estimates As Q4 Results Top Estimates | WASHINGTON (dpa-AFX) - While reporting financial results for the fourth quarter on Friday, healthcare company Centene Corp. (CNC) initiated its earnings, adjusted earnings and total revenue... ► Artikel lesen | |
| QUIDELORTHO | 24,800 | 0,00 % | QuidelOrtho Corp - 8-K, Current Report | ||
| VERU | 2,340 | +4,46 % | Veru Inc.: Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th | ||
| NANO-X IMAGING | 2,440 | +7,02 % | NANO-X IMAGING LTD: Nanox Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems | This clearance enables the next phase of development aimed ultimately at removing the adjunct use in the US The newly cleared capability provides radiologists with a 2D image generated directly from... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets | All-stock transaction brings Tempest a portfolio of next-generation CAR-T assets, including TPST-2003, a clinical-stage dual-targeting CD-19/BCMA CAR-T with strategic partner-funded BLA filing in... ► Artikel lesen | |
| FULGENT GENETICS | 19,700 | -1,00 % | FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform | ||
| LANTHEUS | 54,48 | -0,69 % | Lantheus Holdings, Inc.: Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies | BEDFORD, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 4,000 | +1,52 % | Perspective Therapeutics Prices Approx. $175 Mln Offering Of Shares And Pre-Funded Warrants | ||
| AMN HEALTHCARE SERVICES | 17,600 | +2,33 % | AMN HEALTHCARE SERVICES INC - 8-K, Current Report |
ACLARION INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,290 (-13,88 %) liegt der Kurs bei 1,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACLARION INC finden Sie auf Wallstreet Online.